Major Finding: Both newly trained and experienced physicians had at least a 97% success rate for placing the Essure 305 inserts in both fallopian tubes in one postmarketing study. The rate of adverse events due to nickel hypersensitivity was lower than expected in a second study.
Data Source: The first postmarketing study included 578 women. The second postmarketing study looked at nickel hypersensitivity.
Disclosures: Dr. Levie and Dr. Zurawin are both on the medical advisory board of Conceptus Inc. Dr. Levie also serves as a physician educator for the company.
PREVIEW